 It was investigated clinically as a treatment for breast cancer and was found to be effective.However, its effectiveness was found to be no better than that of an estrogen alone, and the combination was ultimately never marketed.Gestonorone caproate was studied by Schering for use as a progestogen-only injectable contraceptive across a dose range of 2.5 to 200 mg once every one or two months but was never marketed.